May announce BK this week sometime!
What I hit the bullseye? Typical excuse to steal and cheat to justify their means!
So fitting indeed! LOL!!!
Madoff second in line!
“Valeant has never bought high-quality assets,” said Vicki Bryan, a high-yield analyst at Gimme Credit, an independent credit research firm. “They were able to pay high multiples, more than a company is worth, because the high-yield market was so agreeable.”
Consider Valeant’s purchase of Sprout Pharmaceuticals for $1 billion in October. The maker of a female libido drug, Addyi, that has largely failed to attract users, Sprout has fallen far short of its promise. One of the factors contributing to Valeant’s reduced revenue expectations for 2016 was underperformance in its women’s health business, the company said.
Valeant’s $8.7 billion purchase of Bausch & Lomb in 2013 is another example. Ms. Bryan said that between declining sales and legal issues surrounding some of its products, Bausch & Lomb was “really struggling.”
The company’s $10 billion purchase in February 2015 of Salix, known for Xifaxan, a drug for the treatment of irritable bowel syndrome, also appears to be in question. Valeant said that “more modest growth in Salix” was a reason for its lower revenue forecasts for 2016.
Ms. Little of Valeant disputed Ms. Bryan’s views. “Bausch & Lomb was acquired in 2013 and has consistently delivered strong organic growth,” she said, adding that Salix “was acquired just under one year ago, and Xifaxan is on track to be Valeant’s first $1 billion product.” She also said that the company had no plans for major divestments.
Jublia, a product for toenail fungus, was once considered a big drug for Valeant. In the company’s presentation to investors on Tuesday, though, Valeant said Jublia’s fourth-quarter 2015 sales had fallen 36 percent from the quarter before. Nor did Jublia make it onto Valeant’s most recent list of drugs with a double-digit growth potential over the next three years.
Valeant investors are learning an age-old market lesson the hard way: A company’s assets may shrink but its debt doesn’t. And as Ms. Bryan noted, Valeant’s debt load puts it in
The Monkey has more chances to beat the market than Ackman's Vanishing Capital trading for dummies! LOL!!!
Total Cash (mrq): 1.44B
Total Cash Per Share (mrq): 4.18
Total Debt (mrq): 30.88B
Total Debt/Equity (mrq): 477.72
Current Ratio (mrq): 1.50
Book Value Per Share (mrq): 18.49
Why do we always get these clown posting the same old #$%$! If you really did buy at $58 you are a bigger idiot than I thought! Those who bought at 40,30 and 20 are less of a fool but still brain dead!
Ponzi scheme and book manipulation, financial reinstatement!
Ponzi as it gets!
Thing get worst by the days for Achman the dirtbag weasel! Karma is a "B"!
Bill Snakeman saids "Trust Me Angel dust really exists!" Not...................
Why do your type always cry foul or antisemitism! Just man up and admit you did wrong and cheated. Instead, you guys just justify to steal,cheat and hurt others!
$25 next and down to $18!
Wait and see on this one trick pony!
And to think Ackman was all along pumping a Ponzi Scheme on other stocks like HLF when VRX was right infront of our own eyes. VRX the real Ponzi scheme pumped by Ackman the dirtbag weasel selling snake oil!